Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > “Second mouse gets the cheese “

<< Previous

Bullboard Posts

Next >>

Comment by CaseyLon Jan 03, 2024 7:00pm

168 Views

Post# 35809684

RE:RE:RE:RE:RE:RE:RE:RE:RE:“Second mouse gets the cheese “

I'm absolutely passive aggressive. I have a ton of money invested, and I've always been passive aggressive. I don't need to be morally correct or sound to want the right thing here. And yes, I can say some pretty crappy things. But one thing is true. We will prevail! The day I see Oncolytics succeed is the day I'm internally smitten, forever and always.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023